Adlai Nortye Ltd.
ANL
Rank in Stocks
#11209
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the... Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is in Phase Ib clinical trials, exploring its efficacy in treating various conditions, including: recurrent non-small cell lung cancer; urothelial cancer (post-anti-PD-1/PD-L1 treatments); recurrent triple-negative breast cancer; microsatellite stable colorectal cancer; and cervical cancer (following standard-of-care treatments). Additionally, ANL is developing AN4005, an oral small-molecule PD-L1 inhibitor. This drug, which is in Phase I clinical trials, aims to induce and stabilize PD-L1 dimerization to disrupt the interaction between PD-1 and PD-L1. Beyond their clinical programs, Adlai Nortye has early-stage research candidates such as AN8025, a multifunctional antibody that acts as a modulator of T cells and antigen-presenting cells, and AN9025, an oral small molecule pan-KRAS inhibitor. Established in 2004, the company's headquarters are situated in Grand Cayman, Cayman Islands.
Share Price
$11.15
Last synced: 2026-11-09
Market Cap
$591.84M
Change (1 day)
8.46%
Change (1 year)
588.27%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Adlai Nortye Ltd. (ANL)
Category
Healthcare
Operating Margin for Adlai Nortye Ltd. (ANL)
Operating Margin as of November 2026 TTM: -113.28%
According to Adlai Nortye Ltd.'s latest financial reports, its current operating margin (TTM) is -113.28%. At the end of 2025 the company had an operating margin of -713.96%.
Operating Margin history for Adlai Nortye Ltd. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -113.28% | -84.13% |
| 2025 | -713.96% | 0.00% |
| 2024 | 0.00% | -100.00% |
| 2023 | -1,352.20% | 0.00% |
| 2022 | 0.00% | -100.00% |
| 2021 | -18.91% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.34% |
US
|
|
| -149.01% | -98.68% |
US
|
|
| 25.57% | -100.23% |
AU
|
|
| 31.23% | -100.28% |
BE
|
|
| 29.35% | -100.26% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Adlai Nortye Ltd.'s operating margin
What is Adlai Nortye Ltd.'s operating margin?
Adlai Nortye Ltd.'s operating margin is -113.28%, as of Nov 2026.
What was Adlai Nortye Ltd.'s operating margin in 2025?
In 2025, Adlai Nortye Ltd.'s operating margin was -713.96%, compared with 0.00% in 2024.
How has Adlai Nortye Ltd.'s operating margin changed since 2020?
From 2020 to 2025, Adlai Nortye Ltd.'s operating margin was highest in 2024 (0.00%) and lowest in 2023 (-1,352.20%).
How does Adlai Nortye Ltd.'s operating margin compare with similar companies?
Adlai Nortye Ltd.'s operating margin (-113.28%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.